Everest Medicines (STU:6HN) Moat Score: 0/10 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6HN Everest Medicines Ltd STU:6HN
51 GF Score
Price €2.80
GF Value €32.66
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Everest Medicines Moat Score?

Everest Medicines has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Everest Medicines has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Everest Medicines might have No Moat - No discernible moat.

Everest Medicines  (STU:6HN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Everest Medicines Moat Score Related Terms

STU:6HN
51GF Score
Everest Medicines Ltd STU:6HN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Everest Medicines (STU:6HN) Overvalued in 2026?

Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued. The current stock price of €2.80 is trading 91.4% below its estimated GF Value™ of €32.66. GuruFocus considers Everest Medicines to be Possible Value Trap.

Key valuation signals for STU:6HN:

  • Moat Score: 0
  • GF Value™: €32.66 vs. price of €2.80 (91.4% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:6HN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Everest Medicines Business Description

Other Exchanges 01952:Hong Kong
Address AIA Financial Center, 866 East Changzhi Road, 17th Floor, Hongkou District, Shanghai, CHN, 200082
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
51GF Score

Get the complete analysis for STU:6HN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.80
Price
€32.66
GF Value